6FK.F GENTIAN DIAGNOST. NO -01

Healthcare Health Care Equipment & Supplies Frankfurt Exchange
3.70 EUR
Close of Nov 11, 2026
3.08 5.13
Market cap
EUR 57.2M
P/E
-
P/B
3.18x
ROE
-6.0%
Dividend yield
1.52%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 6FK.F undervalued?

Graham number

The Graham number of GENTIAN DIAGNOST. NO -01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GENTIAN DIAGNOST. NO -01 fundamental analysis

No fundamental analysis for GENTIAN DIAGNOST. NO -01 yet.

GENTIAN DIAGNOST. NO -01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GENTIAN DIAGNOST. NO -01

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for th…

Full company profile